|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MRPS7 |
Gene summary for MRPS7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MRPS7 | Gene ID | 51081 |
| Gene name | mitochondrial ribosomal protein S7 | |
| Gene Alias | COXPD34 | |
| Cytomap | 17q25.1 | |
| Gene Type | protein-coding | GO ID | GO:0000028 | UniProtAcc | A0A024R8L0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51081 | MRPS7 | LZE2T | Human | Esophagus | ESCC | 6.77e-07 | 1.24e+00 | 0.082 |
| 51081 | MRPS7 | LZE4T | Human | Esophagus | ESCC | 2.91e-21 | 6.59e-01 | 0.0811 |
| 51081 | MRPS7 | LZE5T | Human | Esophagus | ESCC | 4.60e-03 | 4.17e-01 | 0.0514 |
| 51081 | MRPS7 | LZE7T | Human | Esophagus | ESCC | 9.82e-16 | 9.26e-01 | 0.0667 |
| 51081 | MRPS7 | LZE8T | Human | Esophagus | ESCC | 1.02e-20 | 7.70e-01 | 0.067 |
| 51081 | MRPS7 | LZE20T | Human | Esophagus | ESCC | 2.37e-09 | 4.40e-01 | 0.0662 |
| 51081 | MRPS7 | LZE22D1 | Human | Esophagus | HGIN | 1.38e-09 | 3.28e-01 | 0.0595 |
| 51081 | MRPS7 | LZE22T | Human | Esophagus | ESCC | 2.18e-08 | 7.10e-01 | 0.068 |
| 51081 | MRPS7 | LZE24T | Human | Esophagus | ESCC | 2.24e-40 | 1.21e+00 | 0.0596 |
| 51081 | MRPS7 | LZE22D3 | Human | Esophagus | HGIN | 1.05e-03 | 7.48e-01 | 0.0653 |
| 51081 | MRPS7 | LZE21T | Human | Esophagus | ESCC | 2.16e-09 | 8.69e-01 | 0.0655 |
| 51081 | MRPS7 | LZE6T | Human | Esophagus | ESCC | 3.32e-11 | 8.46e-01 | 0.0845 |
| 51081 | MRPS7 | P1T-E | Human | Esophagus | ESCC | 2.35e-15 | 7.76e-01 | 0.0875 |
| 51081 | MRPS7 | P2T-E | Human | Esophagus | ESCC | 7.22e-71 | 1.17e+00 | 0.1177 |
| 51081 | MRPS7 | P4T-E | Human | Esophagus | ESCC | 2.69e-46 | 1.15e+00 | 0.1323 |
| 51081 | MRPS7 | P5T-E | Human | Esophagus | ESCC | 1.75e-41 | 8.40e-01 | 0.1327 |
| 51081 | MRPS7 | P8T-E | Human | Esophagus | ESCC | 2.13e-44 | 1.01e+00 | 0.0889 |
| 51081 | MRPS7 | P9T-E | Human | Esophagus | ESCC | 1.92e-41 | 1.00e+00 | 0.1131 |
| 51081 | MRPS7 | P10T-E | Human | Esophagus | ESCC | 1.04e-66 | 1.24e+00 | 0.116 |
| 51081 | MRPS7 | P11T-E | Human | Esophagus | ESCC | 2.26e-32 | 1.45e+00 | 0.1426 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004227418 | Prostate | BPH | ribosomal small subunit biogenesis | 25/3107 | 73/18723 | 1.82e-04 | 1.53e-03 | 25 |
| GO:00325433 | Prostate | BPH | mitochondrial translation | 23/3107 | 76/18723 | 2.21e-03 | 1.22e-02 | 23 |
| GO:01400532 | Prostate | BPH | mitochondrial gene expression | 29/3107 | 108/18723 | 4.68e-03 | 2.25e-02 | 29 |
| GO:002261319 | Prostate | Tumor | ribonucleoprotein complex biogenesis | 159/3246 | 463/18723 | 3.17e-19 | 1.52e-16 | 159 |
| GO:007182619 | Prostate | Tumor | ribonucleoprotein complex subunit organization | 91/3246 | 227/18723 | 3.62e-16 | 7.50e-14 | 91 |
| GO:002261819 | Prostate | Tumor | ribonucleoprotein complex assembly | 89/3246 | 220/18723 | 3.94e-16 | 7.89e-14 | 89 |
| GO:004225419 | Prostate | Tumor | ribosome biogenesis | 96/3246 | 299/18723 | 2.76e-10 | 1.51e-08 | 96 |
| GO:004225519 | Prostate | Tumor | ribosome assembly | 29/3246 | 61/18723 | 5.06e-08 | 1.54e-06 | 29 |
| GO:000002819 | Prostate | Tumor | ribosomal small subunit assembly | 12/3246 | 19/18723 | 1.09e-05 | 1.56e-04 | 12 |
| GO:004227419 | Prostate | Tumor | ribosomal small subunit biogenesis | 26/3246 | 73/18723 | 1.36e-04 | 1.26e-03 | 26 |
| GO:003254312 | Prostate | Tumor | mitochondrial translation | 24/3246 | 76/18723 | 1.73e-03 | 1.03e-02 | 24 |
| GO:014005311 | Prostate | Tumor | mitochondrial gene expression | 31/3246 | 108/18723 | 2.31e-03 | 1.30e-02 | 31 |
| GO:002261329 | Skin | cSCC | ribonucleoprotein complex biogenesis | 302/4864 | 463/18723 | 5.13e-72 | 3.22e-68 | 302 |
| GO:004225428 | Skin | cSCC | ribosome biogenesis | 206/4864 | 299/18723 | 3.33e-55 | 1.04e-51 | 206 |
| GO:007182629 | Skin | cSCC | ribonucleoprotein complex subunit organization | 140/4864 | 227/18723 | 5.54e-30 | 3.16e-27 | 140 |
| GO:002261829 | Skin | cSCC | ribonucleoprotein complex assembly | 136/4864 | 220/18723 | 2.60e-29 | 1.25e-26 | 136 |
| GO:004227429 | Skin | cSCC | ribosomal small subunit biogenesis | 59/4864 | 73/18723 | 1.39e-22 | 2.90e-20 | 59 |
| GO:004225529 | Skin | cSCC | ribosome assembly | 44/4864 | 61/18723 | 5.84e-14 | 3.81e-12 | 44 |
| GO:00325436 | Skin | cSCC | mitochondrial translation | 47/4864 | 76/18723 | 4.70e-11 | 2.22e-09 | 47 |
| GO:01400535 | Skin | cSCC | mitochondrial gene expression | 56/4864 | 108/18723 | 8.06e-09 | 2.56e-07 | 56 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0301039 | Esophagus | HGIN | Ribosome | 108/1383 | 167/8465 | 1.44e-45 | 4.71e-43 | 3.74e-43 | 108 |
| hsa03010115 | Esophagus | HGIN | Ribosome | 108/1383 | 167/8465 | 1.44e-45 | 4.71e-43 | 3.74e-43 | 108 |
| hsa03010211 | Esophagus | ESCC | Ribosome | 129/4205 | 167/8465 | 1.43e-13 | 3.43e-12 | 1.75e-12 | 129 |
| hsa03010310 | Esophagus | ESCC | Ribosome | 129/4205 | 167/8465 | 1.43e-13 | 3.43e-12 | 1.75e-12 | 129 |
| hsa0301022 | Liver | Cirrhotic | Ribosome | 127/2530 | 167/8465 | 2.12e-35 | 7.06e-33 | 4.35e-33 | 127 |
| hsa0301032 | Liver | Cirrhotic | Ribosome | 127/2530 | 167/8465 | 2.12e-35 | 7.06e-33 | 4.35e-33 | 127 |
| hsa0301042 | Liver | HCC | Ribosome | 128/4020 | 167/8465 | 7.32e-15 | 2.23e-13 | 1.24e-13 | 128 |
| hsa0301052 | Liver | HCC | Ribosome | 128/4020 | 167/8465 | 7.32e-15 | 2.23e-13 | 1.24e-13 | 128 |
| hsa0301030 | Oral cavity | OSCC | Ribosome | 128/3704 | 167/8465 | 2.42e-18 | 1.62e-16 | 8.25e-17 | 128 |
| hsa03010114 | Oral cavity | OSCC | Ribosome | 128/3704 | 167/8465 | 2.42e-18 | 1.62e-16 | 8.25e-17 | 128 |
| hsa03010210 | Oral cavity | LP | Ribosome | 127/2418 | 167/8465 | 1.22e-37 | 4.05e-35 | 2.61e-35 | 127 |
| hsa0301038 | Oral cavity | LP | Ribosome | 127/2418 | 167/8465 | 1.22e-37 | 4.05e-35 | 2.61e-35 | 127 |
| hsa0301029 | Prostate | Tumor | Ribosome | 104/1791 | 167/8465 | 3.53e-31 | 5.84e-29 | 3.62e-29 | 104 |
| hsa0301037 | Prostate | Tumor | Ribosome | 104/1791 | 167/8465 | 3.53e-31 | 5.84e-29 | 3.62e-29 | 104 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MRPS7 | SNV | Missense_Mutation | rs373944549 | c.655G>A | p.Val219Met | p.V219M | Q9Y2R9 | protein_coding | tolerated(0.06) | possibly_damaging(0.882) | TCGA-AN-A0AJ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MRPS7 | SNV | Missense_Mutation | c.568N>C | p.Glu190Gln | p.E190Q | Q9Y2R9 | protein_coding | tolerated(0.06) | probably_damaging(0.996) | TCGA-B6-A0I2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MRPS7 | deletion | Frame_Shift_Del | novel | c.170delN | p.Glu57GlyfsTer2 | p.E57Gfs*2 | Q9Y2R9 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| MRPS7 | insertion | In_Frame_Ins | novel | c.171_172insACTACCTCTCGC | p.Glu57_Leu58insThrThrSerArg | p.E57_L58insTTSR | Q9Y2R9 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| MRPS7 | SNV | Missense_Mutation | novel | c.333N>A | p.Met111Ile | p.M111I | Q9Y2R9 | protein_coding | tolerated(0.32) | benign(0.009) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MRPS7 | SNV | Missense_Mutation | c.191A>G | p.Tyr64Cys | p.Y64C | Q9Y2R9 | protein_coding | tolerated(0.17) | possibly_damaging(0.502) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| MRPS7 | SNV | Missense_Mutation | novel | c.243N>C | p.Lys81Asn | p.K81N | Q9Y2R9 | protein_coding | tolerated(0.49) | benign(0.006) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| MRPS7 | SNV | Missense_Mutation | c.403G>A | p.Ala135Thr | p.A135T | Q9Y2R9 | protein_coding | tolerated(0.16) | possibly_damaging(0.524) | TCGA-D5-6930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| MRPS7 | insertion | In_Frame_Ins | novel | c.481_482insGGC | p.Ile161delinsArgLeu | p.I161delinsRL | Q9Y2R9 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| MRPS7 | insertion | Frame_Shift_Ins | novel | c.484dupC | p.Leu162ProfsTer29 | p.L162Pfs*29 | Q9Y2R9 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |